DRONTAL PLUS FLAVOUR TABLETS FOR DOGS

Country: Írland

Tungumál: enska

Heimild: HPRA (Health Products Regulatory Authority)

Virkt innihaldsefni:

PRAZIQUANTEL, PYRANTEL EMBONATE, FEBANTEL

Fáanlegur frá:

Bayer Limited

ATC númer:

QP52AF30

INN (Alþjóðlegt nafn):

PRAZIQUANTEL, PYRANTEL EMBONATE, FEBANTEL

Skammtar:

50/144/150

Lyfjaform:

Tablets

Gerð lyfseðils:

CAM-Companion Animal Medicine

Meðferðarhópur:

Canine

Lækningarsvæði:

Combinations of tetrahydropyrimidines

Ábendingar:

Endoparasiticide

Leyfisstaða:

Authorised

Leyfisdagur:

2009-01-25

Vara einkenni

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Drontal Plus Flavour Tablets for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
A light brown to brown, round, flat tablet, cross scored on one side
for oral administration to dogs.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control of the following gastrointestinal tapeworms and
roundworms in dogs and puppies.
Ascarids:
_Toxocara canis, Toxascaris leonina_ (adult and late immature forms).
Hookworms:
_Uncinaria stenocephala, Ancylostoma caninum_ (adults)
Whipworms:
_Trichuris vulpis_ (adults)
Tapeworms:
_Echinococcus_ spp.,_ Taenia_ spp.,_ Dipylidium caninum_ (adult and
immature forms)
4.3 CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
As a precautionary measure to prevent
establishment
of
_Echinococcus multilocularis_
in the UK and Ireland it
is
recommended that all dogs and cats entering the country be treated
with praziquantel.
Fleas serve as intermediate hosts for one common type of
tapeworm-_Dipylidium caninum_.
Tapeworm infestation is
certain to re-occur unless control of intermediate hosts such as
fleas, mice etc is undertaken.
Each tablet contains:
mg per tablet
Febantel
150.0
Pyrantel embonate
144.0
Praziquantel
50.0
EXCIPIENTS
Artificial beef flavour, irradiated
116.5
For the full list of excipients see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_